0.94
+0.0099(+1.06%)
Currency In USD
| Previous Close | 0.93 |
| Open | 0.94 |
| Day High | 1.01 |
| Day Low | 0.9 |
| 52-Week High | 2.22 |
| 52-Week Low | 0.54 |
| Volume | 26,146 |
| Average Volume | 164,885 |
| Market Cap | 9.53M |
| PE | -0.52 |
| EPS | -1.82 |
| Moving Average 50 Days | 0.83 |
| Moving Average 200 Days | 0.89 |
| Change | 0.01 |
If you invested $1000 in Biofrontera Inc. (BFRI) since IPO date, it would be worth $10.66 as of August 19, 2025 at a share price of $0.94. Whereas If you bought $1000 worth of Biofrontera Inc. (BFRI) shares 3 years ago, it would be worth $40.87 as of August 19, 2025 at a share price of $0.94.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Biofrontera Inc. Appoints George Jones as Chief Commercial Officer
GlobeNewswire Inc.
Aug 11, 2025 8:25 PM GMT
Woburn, MA, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (the “Company”), a biopharmaceutical company focused on the development and commercialization of photodynamic therapy (PDT), today announced the appointment of George Jon
Biofrontera Inc. to Report Second Quarter FY 2025 Financial Results on August 13, 2025
GlobeNewswire Inc.
Aug 04, 2025 6:00 PM GMT
Woburn, MA, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc., (Nasdaq:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the commercialization of dermatological products, announces it will report financial results
Biofrontera Inc. Announces Major Restructuring of Relationship With Biofrontera AG Backed By $11 Million Investment
GlobeNewswire Inc.
Jun 30, 2025 12:00 PM GMT
Biofrontera Inc. has signed an agreement to acquire all US assets related to Ameluz® and RhodoLED® including New Drug Application (NDA) and associated patents from Germany-based Biofrontera AG.Under their new agreement, the effective royalty rate pai